Reflux inhibitor drugs: An emerging novel therapy for gastroesophageal reflux disease
Author:
- 24 March 2010
- journal article
- review article
- Published by Wiley in Journal of Digestive Diseases
- Vol. 11 (2) , 72-75
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- (R)-(3-Amino-2-fluoropropyl) Phosphinic Acid (AZD3355), a Novel GABAB Receptor Agonist, Inhibits Transient Lower Esophageal Sphincter Relaxation through a Peripheral Mode of ActionThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Emerging drugs for gastroesophageal reflux diseaseExpert Opinion on Emerging Drugs, 2009
- Does the Presence of a Hiatal Hernia Affect the Efficacy of the Reflux Inhibitor Baclofen During Add-On Therapy?American Journal of Gastroenterology, 2009
- 490 Arbaclofen Placarbil Monotherapy Decreases GERD Symptoms in Subjects with Previous PPI TherapyGastroenterology, 2009
- Pathogenesis of gastro‐oesophageal reflux disease and novel options for its therapyNeurogastroenterology & Motility, 2008
- Composition of the postprandial refluxate in patients with gastroesophageal reflux diseaseAmerican Journal of Gastroenterology, 2001
- Activation of the GABAB receptor inhibits transient lower esophageal sphincter relaxations in dogsGastroenterology, 1999
- Heartburn treatment in primary care: randomised, double blind study for 8 weeksBMJ, 1999
- Transient lower esophageal sphincter relaxationGastroenterology, 1995
- Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects.Journal of Clinical Investigation, 1980